Abstract 039: Comparison of Costs & Outcomes of Dapagliflozin With Dipeptidyl Peptidase-4 Inhibitors Added to Metformin Using a Short-term Cost-effectiveness Model

Background: Several long-term models have been developed to compare the economic impact of alternative anti-diabetic treatments. However short-term models, based on actual trial data, might give more accurate results and be preferable over long-term models for estimating costs and benefits in short term. Objective: To assess the economic impact of the antidiabetic drug dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, and dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with metformin in the treatment of T2D. Methods: A short-term decision-analytic model with one year time horizon was developed using a payer’s perspective for United States (US). Costs and benefits associated with four clinical end points (glycated hemoglobin [HbA1c], body weight, systolic blood pressure (SBP), and risk of hypoglycemia) were evaluated in the analysis. A network meta-analysis was utilized to evaluate the impact of DAPA vs. DPP-4i on these clinical end points. Data for costs and QALYs associated w...